OncoMatch/Clinical Trials/NCT04110301
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Is NCT04110301 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Recombinant Humanized Monoclonal Antibody MIL62 and Lenalidomide for follicular lymphoma and marginal zone lymphoma.
Treatment: Recombinant Humanized Monoclonal Antibody MIL62 · Lenalidomide — This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 positive
histologically documented CD20-positive MZL or FL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any anti-lymphoma therapy
Evidence of progression or lack of response following at least 1 prior treatment
Cannot have received: antibody therapy (except Rituximab)
Exception: Rituximab allowed
Prior use of any antibody therapy(except for Rituximab ) within 3 months of study start
Cannot have received: anti-cancer vaccine
Prior use of any anti-cancer vaccine
Cannot have received: radiotherapy
Prior administration of radiotherapy 42 days prior to study entry
Cannot have received: chemotherapy
Prior administration of chemotherapy 28 days prior to study entry
Lab requirements
Blood counts
adequate hematologic function (unless abnormalities are related to nhl)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04110301 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody therapy (except Rituximab), anti-cancer vaccine, radiotherapy disqualifies patients from enrollment.
Does this trial require MS4A1?
Yes, MS4A1 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages